Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Breast Neoplasms 24Carcinoma, Non-Small-Cell Lung 12Precursor Cell Lymphoblastic Leukemia-Lymphoma 6Pancreatic Neoplasms 5Neoplasms 5Lung Neoplasms 5Leukemia, Myeloid, Acute 5Triple Negative Breast Neoplasms 4Melanoma 4Leukemia, Myelomonocytic, Chronic 4Carcinoma, Renal Cell 4Breast Diseases 4Urinary Bladder Neoplasms 3Thoracic Neoplasms 3Respiratory Tract Neoplasms 3Lymphoma 3Lung Diseases 3Leukemia, Myelomonocytic, Acute 3Kidney Neoplasms 3Fallopian Tube Neoplasms 3Congenital Abnormalities 3Colonic Neoplasms 3Bronchial Neoplasms 3Vulvar Neoplasms 2Vaginal Neoplasms 2Uveal Melanoma 2Uterine Cervical Neoplasms 2Sezary Syndrome 2Recurrence 2Rectal Neoplasms 2

Interventions

Fulvestrant 19Letrozole 8Anastrozole 6Capecitabine 5palbociclib 4olaparib 4Paclitaxel 4Injections 4Goserelin 4Docetaxel 4pyrotinib 3exemestane 3trastuzumab deruxtecan 2toripalimab 2sacituzumab govitecan 2ribociclib 2eribulin 2elacestrant 2abemaciclib 2Vinorelbine 2Trastuzumab 2FCN-437c 2Everolimus 2Dasatinib 2Aromatase Inhibitors 2Alpelisib 2Albumin-Bound Paclitaxel 2AZD9833 2vandetanib 1talazoparib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Advanced Breast Cancer × entinostat × Clear all
NCT03538171 2021-07-09

Ph3 Study of Exemestane With or Without Entinostat in Chinese Patients With Hormone Receptor-Positive, Locally Advanced or Metastatic Breast Cancer

Taizhou EOC Pharma Co., Ltd.

Phase 3 Unknown
375 enrolled
Breast

Advanced Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡